Investors are racing to buy TrovaGene Inc (NASDAQ:TROV) shares after the U.S.
AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced the successful completion of a pre-planned futility analysis of the Phase 3 TIVO-3 trial, the Company’s randomized, controlled, multi-center, …
Synchronoss’s shares rocket after Siris returned to the table to discuss potential buyout.
BTIG feels confident in Vericel core business as ixmyelocel-T’s future became uncertain.
Of all the camera makers in all the towns in all the world… GoPro was not expecting Google’s newest: Clips.
RBC Capital casts limelight on Netflix’s price lifts as key revenue growth catalyst.
The analyst can’t help asking: Where’s Tesla’s profit to be justifying such a massively escalated valuation?
ACAD receives BTD in dementia-related psychosis; Initiates DRP phase 3 trial; Phase 2 SERENE trial discontinued.
Drug maker Omeros Corporation (NASDAQ:OMER) announced that it entered into a settlement agreement with Par Pharmaceutical and its subsidiary Par Sterile Products, resolving …
TEVA needs a long-term solution after MYL’s generic Copaxone approval; VRX works on its debt problem.